Monday newspaper round-up: Rail fares, Amazon, working from home
By Michele Maatouk
Date: Monday 06 Feb 2023
(Sharecast News) - Return tickets will be scrapped and new digital ticketing introduced under reforms of the British rail system expected to be announced this week. The two-way tickets, which offer a discounted rate, will be replaced by "single-leg pricing" which will mean that the price of two singles will be the same as the current return fare, according to the Telegraph. The idea was trialled by London North East Railway (LNER) in 2020. - Guardian
The City watchdog is considering easing rules in an attempt to win the $40bn (£34bn) listing of Cambridge-based technology firm Arm Holdings, it has been reported. Officials are said to be locked in talks in a last-ditch attempt to persuade the semiconductor chip-maker's Japanese owner SoftBank to consider a dual listing on the London Stock Exchange alongside New York's Nasdaq technology market, according to the Sunday Times. - Guardian
Amazon is aiming to shed empty warehouses across Britain as it slams the brakes on growth plans after falling to its worst annual loss on record. Amazon is understood to have kicked off work to sublet unused big-box sites in Britain, following years of swooping for more warehouse space across the country. It is estimated to have opened hundreds of warehouses globally during the pandemic, in a bid to make the most of the boom in online spending. - Telegraph
Working from home is fuelling a fraud epidemic, with a growing number of staff falling victim to scams related to their employers. Research by accountants BDO found almost nine in 10 of mid-sized businesses it surveyed had become victims of fraud in 2022, with average losses totalling £219,000 per firm. More than one quarter of these firms also fell victim to fraud at least twice. - Telegraph
The UK is losing out on investment from AstraZeneca to more competitive countries, the head of one of the country's biggest and most valuable companies has warned. Tom Keith-Roach told The Times that AstraZeneca has not made new research and development capital investments in Britain since 2021 and its wider R&D spending in the country could also now be at risk due to the uncompetitive fiscal environment. - The Times
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN